Parkinson's Disease
Recent clinical, regulatory, research and industry developments relating to this disease.
Clinical Study to Investigate the Possible Efficacy and Safety of Montleukast in Parkinson Disease
Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q4 2026.
- Active recent publication activity.
- 2 industry developments reported.
- Q4 2026Clinical Study to Evaluate Safety and Effectiveness of Vinpocetine in Patients With Parkinsonian Disease
- Q3 2027Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach
- Q2 2029A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Q3 2029An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Parkinson's Disease
- Q3 2030Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
Research HighlightsViewHide
Clinical MilestonesView all 14Hide
- 2026-08-06A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's DiseaseResults expected Q2 2029
- 2026-07-21An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Parkinson's DiseaseResults expected Q3 2029
- 2026-07-13Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's DiseaseResults expected Q3 2030
- 2026-02-27Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal ApproachResults expected Q3 2027
- 2025-12-10Clinical Study to Evaluate Safety and Effectiveness of Vinpocetine in Patients With Parkinsonian DiseaseResults expected Q4 2026
- 2026-08-20Clinical Study to Investigate the Possible Efficacy and Safety of Montleukast in Parkinson DiseaseCompleted
- 2026-04-27An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson's DiseaseCompleted
- 2026-02-28TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's DiseaseCompleted
- 2026-02-01A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.Completed
- 2026-02-01A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's DiseaseCompleted
- 2026-12-31Efficacy and Safety of Rasagiline in Prodromal Parkinson's DiseaseWithdrawn
- 2026-02-02A Prospective, Open Label, Single Arm, Clinical Study to Evaluate the Effect of Safinamide on Sleep Quality and Polysomnographic Parameters in Patients With Parkinson's Disease: the Safe Sleep StudyTerminated
- 2026-01-20Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's DiseaseTerminated
Industry & MarketViewHide
- 2026-09-18<![CDATA[Pimavanserin Linked to Fewer Falls Than Other Antipsychotics in Parkinson Disease Psychosis]]>Industry · Psychiatric Times
- 2026-08-19<![CDATA[Neuropsychiatry in the News: Wearable Technology for Parkinson Disease, Ecopipam for Tourette Syndrome]]>Industry · Psychiatric Times
- 2026-12-31ClinicalEfficacy and Safety of Rasagiline in Prodromal Parkinson's DiseaseWithdrawn
- 2026-09-18Industry<![CDATA[Pimavanserin Linked to Fewer Falls Than Other Antipsychotics in Parkinson Disease Psychosis]]>Industry · Psychiatric Times
- 2026-08-20ClinicalClinical Study to Investigate the Possible Efficacy and Safety of Montleukast in Parkinson DiseaseCompleted
- 2026-08-19Industry<![CDATA[Neuropsychiatry in the News: Wearable Technology for Parkinson Disease, Ecopipam for Tourette Syndrome]]>Industry · Psychiatric Times
- 2026-08-06ClinicalA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's DiseaseResults expected Q2 2029
- 2026-07-21ClinicalAn Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Parkinson's DiseaseResults expected Q3 2029
- 2026-07-13ClinicalIntestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's DiseaseResults expected Q3 2030
- 2026-04-27ClinicalAn Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson's DiseaseCompleted
- 2026-03-26ResearchAI-Enabled Flexible Sensing Ecosystems for Parkinson's Disease: Advancing Digital Biomarkers and Closed-Loop Interventions.Jin J · 2026
- 2026-02-28ClinicalTOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's DiseaseCompleted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Product authorisation ended — Ontilyv is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylas… (2025)
Product authorisation ended — Pramipexole Accord is indicated in adults for treatment of the signs and symptoms of idio… (2022)
Original application approval — Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF e… (2019)
Original application approval — Rasagiline ratiopharm is indicated for the treatment of idiopathic Parkinson’s disease (P… (2015)
Original application approval — Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide… (2011)
Original application approval — Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic trea… (2009)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Parkinson Disease96
- Alzheimer Disease29
- Neurodegenerative Diseases28
- Deep Brain Stimulation14
- Gastrointestinal Microbiome14
- Nervous System Diseases7
- Aging6
- Amyotrophic Lateral Sclerosis6
Leading journals6
- International journal of molecular sciences16
- Movement disorders : official journal of the Movement Disorder Society7
- Cells5
- Translational neurodegeneration5
- Brain : a journal of neurology4
- Journal of Parkinson's disease4
Leading researchers8
- Neumann WJ5
- Li Y4
- Calabresi P3
- Ghiglieri V3
- Jankovic J3
- Lang AE3
- Li X3
- Natale G3
Affiliations (unnormalised)6
- School of Medicine9
- College of Pharmacy6
- Department of Clinical Neurosciences6
- Department of Clinical and Movement Neurosciences5
- Charité - Universitätsmedizin Berlin4
- Imperial College London4
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Parkinson disease is a progressive degenerative neurologic disorder marked by resting tremor, bradykinesia, rigidity, postural instability, stooped posture, and a masklike facial expression. It is characterized pathologically by loss of melanin-containing neurons in the substantia nigra and other pigmented brainstem nuclei, with Lewy bodies present in affected regions.
The supplied material does not support a single established cause for Parkinson disease. The literature grounding instead emphasizes that the disease is multifactorial and studied in relation to genetics, microbiology, etiology, and aging.
Parkinson disease involves degeneration of dopaminergic neurons, with oxidative stress, mitochondrial dysfunction, and impaired redox homeostasis implicated in neuronal death. Alpha-synuclein is linked genetically and neuropathologically to the disease, and aberrant soluble oligomeric forms are described as toxic species that disrupt cellular homeostasis and synaptic function. Autophagy, ubiquitin-protein ligase pathways, signal transduction, inflammation, and brain-gut axis or microbiome-related mechanisms are also represented in the grounding as contributing biological processes.
Aging is a major factor associated with Parkinson disease in the supplied literature. The grounding also points to iron, calcium, oxidative stress, mitochondrial dysfunction, and industrialization-related environmental burden as associated factors, but does not establish them as definitive individual risk factors.
Parkinson disease is generally treated with dopaminergic therapy, especially levodopa, and the grounding also includes dopamine as a co-studied therapeutic-related agent. The literature supplied additionally reflects broader drug-therapy and therapy-level interest, but does not support more specific treatment categories beyond symptomatic dopaminergic management.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.